Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Daiichi Sankyo Logs Double-Digit Growth in Q1 as Olmetec Cliff Tails Off; Profit Zooms on AZ Deal, Asset Sale
Daiichi Sankyo’s April-June revenue surged over 10% year on year as the loss-of-exclusivity impact from its flagship hypertension drug Olmetec (olmesartan) tapered off while the anticoagulant Lixiana (edoxaban) continued to grow, the company said on July 31. In the first…
To read the full story
Related Article
- Daiichi Sankyo Enjoys 7.7% Rise in April-December Sales; Enhertu Off to Solid Start
February 3, 2020
- Edoxaban Drives Daiichi Sankyo’s Half-Year Earnings
November 1, 2019
- Daiichi Sankyo Reels from Olmesartan LOE, Logs 3.2% Sales Fall
April 26, 2019
BUSINESS
- Merck Biopharma Starts Japan PIII Trial of LH/FSH Combo
July 17, 2026
- Eisai’s Dayvigo Accepted for EMA Review
July 17, 2026
- AbbVie Files Maviret for Acute Hepatitis C
July 17, 2026
- FRONTEO, Santen Advance AI Drug Discovery Project to Second Phase
July 17, 2026
- Ferring’s Adstiladrin, Boehringer’s Jascayd Hit Market; Haizexin Due July 28
July 16, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…